- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04356209
Improving Theempowerment in Patients With Severe Breast Fibrosis Radio-induced Treated by Pravastatin : Benefit of e-PROs (Electronic " Patient Reported Outcome ") on Breast-related Quality of Life (PRAVACUR-02)
Conserving surgery followed by adjuvant radiotherapy is currently the therapeutic standard for patient with Breast Cancer. Symptoms are common among patients receiving this treatment. Ten percent of them will develop severe and chronic radio-induced toxicities, such as breast radio-induced-fibrosis impairing their quality of life (QoL). Yet, paying attention to symptom improves the empowerment and psychological adjustment to the disease. Web-based systems that can provide electronic-Patient reported Outcomes (e-PRO) have been shown to prompt clinicians to intensify symptom management, to improve symptom control, and to enhance patient-clinician communication patient satisfaction, as well as well-being.Benefits of systems to elicit e-PRO improve reliable measure of health-related quality of life (QoL) remains discussed.
To date, there are few specific treatments for these severe radio-induced fibrosis except the antifibrotic combinaison Pentoxifylline/Vitamin E with inconsistent result.
Since 2000, we and others have developed a mechanistic approach modulating the severity of RIF by targeting the Rho/ROCK/CTGF pathway, especially by inhibiting Rho activation by pravastatin. Our preclinical data, then followed by the Phase II PRAVACUR-01 trial, concluded that the use of pravastatin has an anti-fibrotic action on different experimental models and reduces the severity of the grade of fibrosis in 50% of patients.
Patients can now benefit from this new anti-fibrotic agent.
Taken as a whole, these data encourage combining both drug (pravastatin) and non-pharmacological intervention , in particular e-PRO, in the RIF management.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: BOURGIER MD CELINE
- Phone Number: 0467612354
- Email: celine.bourgier@ivm.unicancer.fr
Study Locations
-
-
-
Montpellier, France, 34298
- Recruiting
- ICM Val d'Aurelle
-
Contact:
- BLEUSE Jean-pierre
- Phone Number: 00467613102
- Email: jean-pierre.bleuse@icm.unicancer.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Breast cancer patients treated by conserving surgery followed by adjuvant RT
- Over 18 years old
- At least, grade 2 breast RIF
- Treatment planning data of breast cancer radiotherapy must be available
The following laboratory values obtained ≤ 15 days prior to randomization:
Serum creatinine ≤ 130 µmol/l; ASAT and ALAT≤ 2N; total bilirubin ≤ 1.5N; CK levels < 3 x ULN, only for the women ≥ 70 years
- Negative pregnancy test (β-HCG dosage) in women of childbearing potential (women not of reproductive potential are female patients who are postmenopausal or permanently sterilized: e.g., tubal occlusion, hysterectomy, bilateral salpingectomy).
- Patient without contraindication to treatment with pravastatin
- Signed and dated written consent
- Patient must be affiliated to a French Social Security System
Exclusion Criteria:
- Any breast cancer recurrences
- Current treatment by : statin, fibrate, ciclosporin, systemic fusidic acid, long-term treatment by corticoids
- History of muscular dystrophy diseases or chronic and/or hereditary muscular diseases
- Untreated hypothyroidism
- Serum creatinine > 130 µmol/l; ASAT and ALAT > 2N; total bilirubin > 1.5N
- CK levels > 3 x ULN in women over 70 years
- Known positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAG) or hepatitis C virus (HCV) antibody
- Pregnant or breastfeeding women
- Women of childbearing potential who are unwilling to employ adequate contraception, from the beginning of the study to 4 weeks after last treatment dose
- Known hypersensitivity to pravastatin, or any constituent of the product.
- Patient with alcohol misuse.
- Patients treated with systemic investigational drugs within the past 30 days
- Legal incapacity or physical, psychological or mental status interfering with the patient's ability to sign the informed consent or to terminate the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: EXPERIMENTAL GROUP
ePRO intervention + PRAVASTATINE treatment
|
Statements of symptoms and patients' health status (PROs) will be collected via a web interface, including access and use in patients with burden symptoms. The platform will include four items concerning 7 side effects of fibrosis of grade > 2 in breast cancer. Patients will be encouraged to evaluate on a 5-point Likert scale the frequency, the intensity and the repercussions on the daily life of some symptoms during the last 7 days, in particular on:
Other Names:
All patients will take Pravastatin 40 mg per day (From Day 0 to Month 12).
|
Other: CONTROL GROUP
PRAVASTATINE treatment ( without ePRO)
|
All patients will take Pravastatin 40 mg per day (From Day 0 to Month 12).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
evaluate the benefit on breast-related quality of life of systematic e-PROs
Time Frame: From randomization to 12 months
|
The BRQoL improvement rate at 12 months, compared with baseline, defined as:
|
From randomization to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
evaluate the patients'HRQoL
Time Frame: at baseline;12,24, 36, 48 and 60 months
|
defined by the Health-related quality of life assessed by the EORTC QLQ-C30 and its module BR23
|
at baseline;12,24, 36, 48 and 60 months
|
estimate the use of antidepressants
Time Frame: From randomization to 12 months
|
defined by the rate and dose of used antidepressants
|
From randomization to 12 months
|
estimate the use of analgesics
Time Frame: From randomization to 12 months
|
defined by the rate and dose of used analgesics
|
From randomization to 12 months
|
estimate the use of anxiolytics
Time Frame: From randomization to 12 months
|
defined by the rate and dose of used anxiolytics
|
From randomization to 12 months
|
Assess the levels of psychological distress
Time Frame: at baseline; at 12, 24, 36, 48 and 60 months
|
assessed by (HADS) Scale : score {min :0 (no Distress) --- max :21 ( Hight Distress) }
|
at baseline; at 12, 24, 36, 48 and 60 months
|
monitor the e-PROs alerts in the experimental group
Time Frame: From randomization to 12 months
|
Timing of the e-PROs alerts and the care management (phone call or planning of a consultation, treatment initiation)
|
From randomization to 12 months
|
characterise the evaluation of the side effects linked to RIF in the experimental group
Time Frame: From randomization to 12 months
|
Evolution of the 7 different e-PROs scores across time (general pain { 0 (no pain)- 4 (high pain)}, anxiety{ 0 (no anxiety)- 4 (high anxiety)}, sadness { 0 (no sad)- 4 (high sad)}, texture of the treated breast{ 0 (no sweeling)- 4 (high sweeling)}, two other symptoms assessed by the PRO-CTCAE scales { 0 (none)- 4 (severe)}, and scores of aesthetic impact assesses by a Visual Analog Scale{ 0 (no impact)- 100 (max impact)}
|
From randomization to 12 months
|
characterise the modifications of the patients' management in the experimental group
Time Frame: From randomization to 12 months
|
Number of hospital emergency visits or hospitalizations
|
From randomization to 12 months
|
evaluate the anti-fibrotic efficacy of pravastatin
Time Frame: From randomization to 12 months
|
Number of supplementary consultations
|
From randomization to 12 months
|
evaluate the pravastatin safety
Time Frame: From randomization to 12 months
|
Regression rate of at least 1 grade of fibrosis (follow-up of fibrosis grade evolution since inclusion)
|
From randomization to 12 months
|
estimate the relapse-free survival
Time Frame: Until study completion: 5 years
|
Relapse-free survival defined as the time from the date of randomization to the date of the first observed oncological event such as local, ipsilateral, regional or metastatic recurrence or death for any cause
|
Until study completion: 5 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PROICM 2019-02 PRA
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
Clinical Trials on e-PRO Intervention
-
Massachusetts General HospitalCenduit LLCUnknownHealthy | Usability | SurveysUnited States
-
Comprehensive Support Project for Oncology ResearchEnrolling by invitationStomach Cancer | Breast Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Squamous Cell Carcinoma of the Head and Neck | Endometrial Cancer | Liver CancerJapan
-
CellMedX CorporationNutrasource Pharmaceutical and Nutraceutical Services, Inc.Completed
-
BBraun Medical SASRecruiting
-
Jens EcksteinPreventicus GmbHCompleted
-
Alberto PilottoCompletedMultimorbid and Poly-treated Older PeopleItaly
-
Xiaodong SunShanghai Zhongshan Hospital; Eye & ENT Hospital of Fudan University; Shanghai... and other collaboratorsUnknownAge-related Macular DegenerationChina
-
Indiana UniversityNational Institute on Aging (NIA)CompletedSubjective Cognitive DeclineUnited States
-
Monash UniversityCompletedDiabetes Mellitus, Type 2 | Intervention Studies | BehaviorMalaysia
-
Hong Kong Baptist UniversityGuangdong Provincial People's HospitalCompletedPhysical Activity | Cardiac Rehabilitation | Fruit and Vegetable IntakeChina